Posts

Posted on

(WDR): Johnson Fistel Investigates Proposed Sale of Waddell & Reed Financial; Are Shareholders Getting a Fair Deal?

PR Newswire

SAN DIEGO, Dec. 3, 2020 /PRNewswire/ — Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Waddell & Reed Financial, Inc. (“Waddell & Reed” or the “Company”) (NYSE: WDR) breached their fiduciary duties in connection with the proposed sale of the Company to) Macquarie Group (“Macquarie”).  

On December 2, 2020, Waddell & Reed announced that it had entered into a definitive merger agreement with Macquarie. Under the terms of the agreement, Waddell & Reed stockholders will receive only $25.00 for each share of Waddell & Reed common stock they own.

The investigation concerns whether the Waddell & Reed board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Waddell & Reed shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given analysts’ projections for future earnings and revenue growth.

If you are a shareholder of
Waddell & Reed
 and believe the proposed buyout price is too low or you’re interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

 

Cision View original content:http://www.prnewswire.com/news-releases/wdr-johnson-fistel-investigates-proposed-sale-of-waddell–reed-financial-are-shareholders-getting-a-fair-deal-301185685.html

SOURCE Johnson Fistel, LLP

Posted on

IIROC Trading Halt – GABY

Canada NewsWire

VANCOUVER, BC, Dec. 3, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: GABY Inc.

CSE Symbol: GABY

All Issues: Yes

Reason: At the request of the Company Pending News

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

Field Trip Health Ltd. Provides Operational and Investor Update, Announces Expanded Hours at its Field Trip Health Center in Toronto plus Rollout of Portal, Field Trip’s Proprietary Digital Mental Health Platform

Expanded clinical hours being offered in response to accelerating interest from people and military veterans seeking treatment with ketamine-assisted therapy, plus launch of Portal enables enhanced experiences and greater access to therapies

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce that, in response to significant interest from people and medical professionals in Canada, it is expanding the hours of operation at its Toronto Field Trip Health location to provide its psychedelic therapies on evenings and Saturdays. Participants receiving Field Trip’s ketamine-assisted therapies will soon be able to book appointments between 8 am and 5pm on Mondays, between 8am and 8pm from Tuesday to Friday and 12pm to 8pm on Saturdays.

Field Trip also reported that this week of November 30 – December 4, 2020 is the busiest week to date at its Toronto Field Trip Health center, achieving a record number of sessions scheduled.

First Canadian Military Veteran Completes Treatment with
Medavie
Blue Cross Reimbursement

Field Trip is also pleased to announce that it has successfully supported an application by a Canadian military veteran to seek reimbursement for Field Trip’s “Core+” program from the Medavie Blue Cross/Veterans Affairs Canada insurance program.

This marks a significant milestone for military veterans wishing to explore psychedelic therapies to help treat the post-traumatic stress and other mental health challenges experienced by military veterans, as insurance coverage will make Field Trip’s treatment programs more affordable and accessible.

Availabil
ity of Portal to People in North America

Portal, Field Trip’s proprietary digital mental health platform, also began rolling out across North America to people currently participating in Field Trip’s psychedelic-enhanced therapy programs. Portal, which meets Canadian and US standards for personal health information compliance, is designed to enhance the therapeutic experience and improve outcomes in Field Trip Health centers and beyond. The platform provides people in Field Trip’s programs with therapeutic information, videos, meditations, mood monitoring and activity tracking tools and will soon offer synchronous and asynchronous communication with their therapy team. For therapists, Portal enables customizable therapeutic journeys for each person in therapy, and can help them track the progress of their clients, target lifestyle considerations to work on and collect feedback.

Portal will feature prominently in Field Trip’s planned expansion efforts, and will act as the foundation of Field Trip’s therapy innovation efforts, combining anonymized data on therapeutic outcomes with data from other tools currently deployed by Field Trip, including its partnership with WHOOP to collect biometric data on participants’ experiences.

Increased Access Fo
r Investors

Finally, in response to accelerating interest from outside Canada, Field Trip also announced today that it is actively exploring options to enhance access to global investors who are interested in investing in Field Trip through recognized exchanges. While Field Trip is currently traded on the Canadian Securities Exchange (CSE) under the ticker FTRP and the OTCBB under the ticker FTRPF, options currently being considered by management include potential up or cross-listing to US or international exchanges and/or uplisting to senior exchanges in Canada.

“At Field Trip, we have always been focussed on the promise of increasing access to, and scaling, psychedelic therapies both through the development of new drugs and products, and building the physical and digital infrastructure necessary to deliver these life-transforming therapies,” said Ronan Levy, Field Trip’s Executive Chairman. “With the first successful reimbursement for a military veteran in Canada, the rollout of Portal across North America and the expanded access at our Toronto location, we continue to live up to that promise.”


About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.


Cautionary Note Regarding Forward-Looking Information.


This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respe
ct to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “be
lieves” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and vi
ews of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be
incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epid
emic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual act
ions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place
undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip d
oes not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this news release.

Media contacts
:

Paige Tatulli
Autumn Communications
212-206-9780
[email protected] / [email protected]

Investor contacts:

Elizabeth Barker
KCSA Strategic Communications
212-896-1203
[email protected]

SOURCE Field Trip Health Ltd.



Posted on

Vinco Ventures Sells Subsidiary SRM Entertainment

Bethlehem, PA, Dec. 03, 2020 (GLOBE NEWSWIRE) — Vinco Ventures, Inc. (Nasdaq:BBIG), a mergers and acquisitions growth company, today announced the successful closing of the sale of its wholly owned subsidiary, SRM Entertainment Ltd. (“SRM”), to Jupiter Wellness, Inc. (Nasdaq:JUPW), a leading developer of skin care and wellness products.

Under the terms of the agreement, Vinco Ventures received 200,000 shares of Jupiter Wellness’ restricted common stock for 100% of the issued and outstanding shares of common stock of SRM. The sale included the transfer of all current SRM employees, the SRM Hong Kong Office and all financial obligations of SRM. The transaction closed on November 30, 2020.

SRM Entertainment’s main operation focused on the sale of products to theme parks and entertainment companies worldwide. “We are satisfied with the completion of this transaction,” said Brian McFadden, Chief Strategy Officer of Vinco Ventures. “This divesture is a true win-win for Vinco and Jupiter Wellness as it allows the Company to increase its capital position while reducing operating expenses and eliminating debt obligations. We feel confident that Jupiter Wellness will benefit from the acquisition as they pursue a new business with the SRM clients,” McFadden continued.

“This is the first of several planned divestures for Vinco as we reposition our holdings for 2021. Through these planned divestures, we will maximize our cash and asset positions while significantly reducing overall expenses. This transaction supports our overall mission statement of “Buy. Innovate. Grow.” as we launch into the new year,” McFadden concluded. “Be BIG.”

About Vinco Ventures, Inc.

Vinco Ventures, Inc. (BBIG) is a mergers and acquisition company focused on digital commerce and consumer brands. Vinco’s B.I.G. (Buy. Innovate. Grow.) strategy will seek out acquisition opportunities that are poised for scale and grow said acquisitions through targeted traffic and content campaigns. For more information, please view our investor presentation or visit Investors.vincoventures.com.

Safe Harbor Statement

To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”) contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,” “projected” and other words or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor Relations:

Aimee Carroll
Phone: (866) 900-0992
Email: [email protected]



Posted on

Jacobs Creating First Digital Twin of PUB’s Changi Water Reclamation Plant in Singapore

The Replica™ whole plant simulation model features real-time data feed and predictive capabilities to test operational changes and improve operator training

PR Newswire

DALLAS, Dec. 3, 2020 /PRNewswire/ — Jacobs (NYSE:J), has partnered with PUB, Singapore’s National Water Agency, in an R&D project to develop and trial a whole plant simulation model for the Changi Water Reclamation Plant (CWRP). The model, a digital twin of the plant, will be the first application of its kind and combines real-time data from supervisory control and data acquisition (SCADA) historian with software simulation packages (Replica™ Digital Twin Platform) to integrate process, hydraulics, controls and advanced data analytics into a single, whole plant simulation capable of replicating plant operations and predicting future performance in real-time. The trial is expected to be completed by December 2020 and this research is supported by the National Research Foundation Singapore and PUB.

“In today’s technology-driven world, digital representations of physical assets, processes and systems – or digital twins – provide unparalleled insight into ongoing plant operations and maintenance, supporting increased productivity, enhancing operational resilience and optimizing energy and chemical consumption,” said Jacobs Vice President and Global Digital Market Director Dr. Raja Kadiyala. “PUB is at the forefront of utilizing this technology to improve its wastewater operations, allowing dynamic analysis of resource supply, demand, cost, risk and other factors throughout its systems to make resilient decisions.”

Working closely with PUB and with support from National Research Foundation Singapore, Jacobs is designing the model with customized user interfaces to improve its functionality and maximize user experiences. Through a secured connection to the SCADA system, the model replicates CWRP’s hydraulic, process, and control components with near real-time data feeds. The data are checked to enhance accuracy before being automatically fed into Replica™ for hydraulics and control simulation and Sumo© for process simulation of the wastewater treatment plant. The model continuously adjusts its calibrations within defined ranges to match the plant’s observed performance via machine learning, ensuring simulations are relevant to real operations, without requiring intervention from staff. The model is also capable of creating customizable scenarios for operator training, thus facilitating knowledge transfer to new staff. The Replica™ whole plant simulation model technology is now being used by Jacobs on water applications globally.

CWRP is one of the world’s largest and most advanced water reclamation plants designed by Jacobs. For more than 20 years, Jacobs has been delivering water and wastewater projects with PUB. Other notable projects include the award-winning Deep Tunnel Sewerage System, the iconic NEWater Plant and Visitor Centre, transforming the Kallang River at Bishan-Ang Mo Kio Park under the Active, Beautiful, Clean Waters (ABC Waters) program and Tuas Desalination Plant.

To learn more about how Jacobs is using predictive analytics to improve water systems, read the latest Forbes column from Jacobs SVP of Technology and Innovation, Heather Wishart-Smith.

At Jacobs, we’re challenging today to reinvent tomorrow by solving the world’s most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With approximately $14 billion in revenue and a talent force of more than 55,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter.

Certain statements contained in this press release constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements, including, but not limited to, the impact of the COVID-19 pandemic and the related reaction of governments on global and regional market conditions and the company’s business. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our Annual Report on Form 10-K for the year ended October 2, 2020, and in particular the discussions contained under Item 1 – Business; Item 1A – Risk Factors; Item 3 – Legal Proceedings; and Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations, as well as the company’s other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

For press/media inquiries:
Kerrie Sparks
214.583.8433

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jacobs-creating-first-digital-twin-of-pubs-changi-water-reclamation-plant-in-singapore-301185525.html

SOURCE Jacobs

Posted on

Inseego MiFi® 8000 Mobile Hotspots Provide Businesses and First Responders Internet Access “Anywhere” with AT&T and FirstNet

Inseego MiFi® 8000 Mobile Hotspots Provide Businesses and First Responders Internet Access “Anywhere” with AT&T and FirstNet

— Best-in-class 4G LTE connectivity for enterprise users and first responders —

SAN DIEGO–(BUSINESS WIRE)–
To meet the urgent need for fast, reliable internet access — virtually anywhere — Inseego (Nasdaq:INSG) today announced that its MiFi® 8000 4G LTE mobile hotspot is now available for AT&T (NYSE:T) enterprise users and first responders using FirstNet® services nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005338/en/

Inseego MiFi® 8000 for AT&T (Photo: Business Wire)

Inseego MiFi® 8000 for AT&T (Photo: Business Wire)

“Our enterprise customers and first responders using FirstNet need secure, reliable connectivity wherever their work takes them, which is why the Inseego MiFi 8000 mobile hotspot is such an important tool,” said Robert Boyanovsky, vice president, Mobility and IoT, AT&T. “We’re proud to meet their needs with this powerful, trusted device.”

“The massive shift to remote work has amplified the need for highly secure, gigabit-speed internet access, both for individual employees working at home and for teams operating in the field,” said Ashish Sharma, president, IoT & Mobile Solutions, Inseego. “We’re thrilled to provide our popular, proven MiFi 8000 mobile hotspot as an AT&T co-branded solution for individuals on AT&T, as well as FirstNet, public safety’s dedicated communications platform.”

Fast, reliable LTE connections anywhere

The award-winning Inseego MiFi 8000 delivers gigabit-class LTE (Cat 18) speeds and enterprise-grade security to users who need reliable, go-anywhere internet access. It connects up to 15 Wi-Fi devices, avoiding network congestion by providing a separate, dedicated internet connection. It also features a USB-C port for direct tethering. Long battery life and quick recharging keeps users connected for hours of continuous use.

Built-in GPS allows users to view the hotspot location via the web interface, which also enables GPS to be turned on and off at a designated time. With a software driver installed, a computer or tablet can also get an accurate GPS location via the hotspot’s Wi-Fi.

Enterprise-grade security

Designed and developed in the U.S., the MiFi 8000 safeguards your data and connections with advanced encryption, hacker prevention, VPN pass-through, password protection, Guest Wi-Fi network and more. The IT admin portal also lets you customize and control the settings.

Compact and user-friendly

The pocket-sized MiFi 8000 goes with you anywhere to deliver fast and reliable internet access, packing best-in-class performance into an easy-to-use device with a large 2.4” color touchscreen and intuitive menus.

Built for the most demanding users

The MiFi 8000 is designed for quality-conscious users, from government workers and enterprise employees to first responders and other public safety workers who need unbeatable security, performance and reliability.

FirstNet Ready™

The MiFi 8000 mobile hotspot is FirstNet Ready™, which means first responders can use it to tap into the power of FirstNet® — which provides public safety the nation’s fastest overall network experience.1 FirstNet Ready™ devices are subject to hundreds of tests that cover several aspects, from security and durability to network impacts. This helps make sure that they can meet the needs of first responders. FirstNet Ready™ devices support access to the dedicated FirstNet network core, FirstNet First Priority® – which includes always-on priority and preemption for first responders – and the Band 14 spectrum.

Pricing and availability

AT&T subscribers for $179.99 or $6.00/mo. for 30 months on a 0% APR installment plan at: https://www.business.att.com/support/contact.html.

To learn more about the Inseego MiFi 8000 for FirstNet, visit: https://www.firstnet.com/devices/invehicle/inseego-mifi-8000.html

About Inseego Corp.

Inseego Corp. (Nasdaq: INSG) is an industry pioneer in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband and fixed wireless access (FWA) solutions incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com

©2020. Inseego Corp. All rights reserved. The Inseego name and logo are trademarks of Inseego Corp. MiFi is a registered trademark of Inseego Corp. in the United States and other countries. Other Company, product or service names mentioned herein are the trademarks of their respective owners.

FirstNet and the FirstNet logo are registered trademarks of the First Responder Network Authority.

1 *Based on AT&T analysis of Ookla® Speedtest Intelligence® data median download speeds for Q3 2020. Ookla trademarks used under license and reprinted with permission.

Media contact:

Anette Gaven

Tel: +1 (619) 993-3058

Email: [email protected]

Or

Investor Relations contact:

Joo-Hun Kim, MKR Group

Tel: +1 (212) 868-6760

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Public Relations/Investor Relations Communications Software Internet Hardware Data Management Consumer Electronics

MEDIA:

Photo
Photo
Inseego MiFi® 8000 for AT&T (Photo: Business Wire)
Photo
Photo
Inseego MiFi® 8000 for FirstNet (Photo: Business Wire)
Posted on

Cannae Holdings, Inc. Announces Promotion of David Ducommun to President

Cannae Holdings, Inc. Announces Promotion of David Ducommun to President

LAS VEGAS–(BUSINESS WIRE)–
Cannae Holdings, Inc. (NYSE:CNNE) (“Cannae” or the “Company”) today announced the promotion of David Ducommun to President effective January 1, 2021, succeeding Brent Bickett who, as previously announced, will transition to the role of Strategic Advisor. In addition to the role of President, Mr. Ducommun will remain Managing Director at Trasimene Capital Management, LLC.

“I would like to congratulate David on his promotion to President.” commented William P. Foley, II, Chairman. “David has been vital to the Cannae team since inception and through the course of his tenure has demonstrated exceptional leadership skills. In promoting David to the senior leadership team he will continue to work directly alongside myself and Richard Massey focused on the advancement of Cannae’s growth initiatives.”

Mr. Ducommun commented, “I am excited to assume the President role as we head into the New Year and am eager to continue growing Cannae through our strategic investments. It is an honor to work alongside industry veterans Bill Foley and Richard Massey. It truly is an exciting time at Cannae with numerous opportunities ahead, and my goal is to further build upon our past successes.”

Mr. Ducommun has more than two decades of significant related experience prior to joining Cannae as Vice President, Corporate Finance in 2017, and most recently as Executive Vice President, Corporate Finance. Previously, Mr. Ducommun served as Senior Vice President of Mergers & Acquisitions of FNF from 2011 to 2019. He has also served as Managing Director, Corporate Finance, of FNFV LLC since July 2014 and as Secretary of CF Corporation since April 2016. Prior to joining FNF, Mr. Ducommun served as Director of Investment Banking at Bank of America Corporation, since 2008. Before Bank of America Corporation, Mr. Ducommun was an investment banker at Bear Stearns.

About Cannae Holdings, Inc.

Cannae Holdings, Inc. (NYSE: CNNE) is engaged in actively managing and operating a group of companies and investments, as well as making additional majority and minority equity portfolio investments in businesses, in order to achieve superior financial performance and maximize the value of these assets. Cannae was founded and is led by investor William P. Foley, II. Foley is responsible for the creation and growth of over $100 Billion in publicly traded companies including Fidelity National Information Services (“FIS”), Fidelity National Financial (“FNF”), and Black Knight, Inc. (“BKI”). Cannae’s current principal holdings include Dun & Bradstreet Holdings, Inc. (“DNB”), which recently completed a successful business transformation and IPO. Cannae holds an approximately 18% interest in Dun & Bradstreet or ~76 million shares. Cannae’s second principal holding is Ceridian (“CDAY”), which Foley transformed from a legacy payroll bureau into a leading cloud based provider of human capital management software. Cannae owns approximately 9.5% of Ceridian representing ~14 million shares.

Jamie Lillis, Managing Director, Solebury Trout, 203-428-3223, [email protected]

Shannon Devine, VP, Solebury Trout, 203-428-3228, [email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients

Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced that Immunoscore® is evaluated in a new study with two cohorts from the prospective randomized IDEA1 international trial in Stage III Colorectal Cancer2: the SCOT3 cohort in the UK4 and the HORG5 cohort in Greece6.

The objectives of the new Immunoscore® study announced today are to consolidate results obtained in the Immunoscore-IDEA France7 study for its predictive and prognostic performance in additional independent series. Moreover, the study will investigate Immunoscore® performance in CAPOX treated patients, in order to assist oncologists to select optimal adjuvant chemotherapy regimen for individual patients. The study will be conducted in 3000 patients receiving either FOLFOX or CAPOX chemotherapy.

Updated results from the parent IDEA collaboration showed that Overall Survival and 5 years Disease Free Survival results continue to support the use of 3 months versus 6 months adjuvant chemotherapy for the vast majority of stage III colon cancer patients, but conclusion underlined oncologists’ needs for more accurate risk profiling beyond Tumor/Node stage classification, such as Immune status scoring (i.e. Immunoscore®), to help define the best adjuvant therapy in Stage III colon cancer.

Pr John Souglakos, MD, PhD, University of Heraklion, Crete, commented:
“
This study will provide additional data on the consistency of evaluating immune response at the tumor site to adjust for optimal treatment duration in stage III colon cancer and more specifically data on a CAPOX cohort will be generated. We are very happy to bring a complementary cornerstone of evidence participating in this randomized clinical study in a multicentric framework”.

Vincent FERT, CEO of HalioDx mentioned:
‘We are delighted to work with experts in GI oncology from UK and Greece and access to FOLFOX and CAPOX patients from IDEA study will strengthen Immunoscore® Level of Evidence in stage III colon cancer.”
 

He added

“
One of our priority is to provide oncologists with best in class precision medicine tools and this study addresses precisely this objective”.

***

About Immunoscore®

Immunoscore® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications (8910).

In 2020, the World Health Organization (WHO), in its latest edition of the Digestive System Tumours, introduced immune response as an essential and desirable diagnostic criterion for colorectal cancer, in addition to traditional histological parameters.

Subsequently, Immunoscore® was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer.

Immunoscore® Colon is the first IVD diagnostic test of our Immunoscore® portfolio for which a comprehensive corpus of clinical data demonstrating its clinical utility associated with TNM scoring in the management of localized colon cancer has been published. Additional immune-based assays in the same portfolio are used as clinical trial assays to support translational research and clinical development. Those assays enable Multiplex Spatial Tissue Analysis and combine proprietary multiplexed immunohistochemistry, advanced image analysis and computerized algorithms.

Immunoscore® is currently being investigated in a broad number of clinical studies and cancer indications for establishing its performance as a prognostic factor as well as a predictive factor for response to drugs, notably chemotherapies and immunotherapies.

Immunoscore® is commercially available in more than 20 countries.

About HalioDx

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions including its flagship Immunoscore® assay for the assessment of the immune contexture of a tumor, as a key determinant of patients’ outcomes and response to cancer treatments.

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies.

For more information, please visit our websites


www.haliodx.com


and


www.immunoscore-colon.com


and follow the company on


Twitter


,


Linkedin


and


Youtube


.

Immunoscore® is a registered trademark of Inserm licenced to HalioDx. Brightplex®, TMExplore™ and Immunosign® are registered trademarks of HalioDx.

Contacts

Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

[email protected]

 ATCG
Partners

Marie Puvieux / Céline Voisin

+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39

[email protected]

1 IDEA: International Duration Evaluation of Adjuvant Chemotherapy

2

Grothey A et al. NEJM, 2018

3 SCOT: Short Course Oncology Treatment trial

4

Iveson TJ et al. Lancet Oncol, 2018

5 HORG: Hellenic Oncology Research Group

6

Souglakos J et al.
Ann Oncol, 2019

7

Pagès F et al. Ann Oncol, 2020

8

Pagès F et al. Lancet. 2018; 391 (10135)

9

Sinicrope FA et al JNCI Cancer Spectrum 2020

10

Pagès F et al. Ann Oncol, 2020

Attachment



Posted on

Completion of Balstilimab BLA Filing Extended To 1H2021

Agenus to fulfill FDA feedback for six-month follow-up on late responders

LEXINGTON, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced updated timing of the balstilimab BLA filing to meet the FDA feedback to follow all patients for a median of 12 months and responders for a minimum of 6 months. Due to two newly-identified late responses in the trial, the completion of the BLA filing is planned for the first half of 2021. In parallel, Agenus is working with the FDA to clarify diagnostic requirements for PD-L1 testing.

The additional follow-up is required to present data on two patients who experienced durable disease stabilization and converted to confirmed responses on long-term balstilimab therapy.


About Agenus


Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.


Forward-Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding regulatory timelines for the BLA filings of balstilimab alone and in combination with zalifrelimab. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Contact:


Agenus Inc. 

Caroline Bafundo
212-994-8209
[email protected]



Posted on

Amadeus Expands Partnership with Couchbase to Help Customers Scale and Adapt to Changing Travel Demand

Leading cloud-native database allows Amadeus to flexibly scale services, better integrate with third parties, and enable greater personalization for customers

LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) — With a keen desire to get back on the road, travelers are cautiously resuming to search for and book flights and hotels. But travel players are facing a challenging new reality – one where performance, flexible operations and personalized service are quickly taking on a whole new meaning in order to remain relevant. 

To this end, Amadeus has extended its partnership with  Couchbase, the creator of the enterprise-class, multi-cloud to edge NoSQL database. The new multi-year agreement will see Amadeus using Couchbase to dynamically scale its levels of service and continue to deploy applications quickly. Couchbase’s versatile and cloud-agnostic database already powers a number of Amadeus applications across search, shopping and merchandising for airline and hotel customers, as well as Traveler-DNA (former Customer Experience Management) – and Amadeus will be adding more in line with evolving industry needs. 

Expanding its use of Couchbase is part of Amadeus’s strategy to continue taking advantage of the cloud and developing new applications to support the industry. Couchbase’s features such as integration with Kubernetes are an important element of this strategy, as well as its ease of use for developers, coupled with the agility and scalability to help solutions ramp up and complete faster. 

As a result, Amadeus developers have quickly adopted Couchbase, seeing a significantly decreased time-to-market thanks to reduced data friction issues and an easier integration with third-party partners. This represents a close fit with Amadeus’ platform approach – allowing engineers to solve a growing number of complex business challenges quickly and efficiently. Ultimately this partnership opens the way towards innovative solutions that can offer greater personalization, an essential need in the current environment.

“Supporting the recovery of the travel industry is our prime objective. We are currently in a highly challenging environment, where the industry is having to react at speed to changing traveler needs and demands.” said Sylvain Roy, SVP, Technology Platforms & Engineering, Amadeus.

Roy continued, “The ability to develop new travel applications and functionality quickly, whilst ensuring those that our customers already rely on continue operating at peak effectiveness, is critical. Couchbase’s database makes it much simpler for our engineers to focus on what they do best: solving our customers’ business challenges – all the while improving collaboration with partners and developers. Our growing partnership will help us deliver the enterprise-class performance, scale, flexibility, reliability and traveler focus that our customers need, enabling us also to innovate more freely in key areas such as merchandising, NDC or loyalty.”

“Amadeus is one of our largest and most important customers, and how they have used our technology is nothing short of impressive,” said Matt Cain, President and CEO, Couchbase. “Amadeus has built a truly scalable platform that enables them to dynamically adjust service levels as needed and simultaneously drive future innovation aligned to their digital transformation initiatives. We are proud of our partnership with Amadeus and the role we’ve been able to play in helping them provide delightful experiences for their customers in ever-changing circumstances. We look forward to further supporting them in powering the recovery of the travel industry.”

 

About Couchbase

Unlike other NoSQL databases, Couchbase provides an enterprise-class, multicloud to edge database that offers the robust capabilities required for business-critical applications on a highly scalable and available platform. As a distributed cloud-native database, Couchbase runs in modern dynamic environments and on any cloud, either customer-managed or fully managed as-a-service. Couchbase is built on open standards, combining the best of NoSQL with the power and familiarity of SQL, to simplify the transition from mainframe and relational databases. 

Couchbase has become pervasive in our everyday lives; our customers include industry leaders Amadeus, American Express, Carrefour, Cisco, Comcast/Sky, Disney, eBay, LinkedIn, Marriott, Tesco, Tommy Hilfiger, United, Verizon, as well as hundreds of other household names. For more information, visit www.couchbase.com.

About Amadeus

Travel powers progress. Amadeus powers travel. Amadeus’ solutions connect travelers to the journeys they want through travel agents, search engines, tour operators, airlines, airports, hotels, cars and railways. 

We have developed our technology in partnership with the travel industry for over 30 years. We combine a deep understanding of how people travel with the ability to design and deliver the most complex, trusted, critical systems our customers need. We help connect over 1.6 billion people a year to local travel providers in over 190 countries. 

We are one company, with a global mindset and a local presence wherever our customers need us. 

Our purpose is to shape the future of travel. We are passionate in our pursuit of better technology that makes better journeys. 

Amadeus is an IBEX 35 company, listed on the Spanish Stock Exchange under AMS.MC. The company is also part of the EuroStoxx50 and has been recognized by the Dow Jones Sustainability Index for the last eight years. 

To find out more about Amadeus, visit www.amadeus.com.

  

© 2020 Couchbase, Inc.  All rights reserved.  Couchbase, the Couchbase logo, and the names and marks associated with Couchbase’s products are trademarks of Couchbase, Inc.  All other trademarks are the property of their respective owners. 



Christina Knittel
Couchbase
7752092461
[email protected]